- ABOUT EUREKA
- NEWS & MEDIA
- CONTACT & SUPPORT
Lanthio Pharma, a biotech startup based in Netherlands is one of the most promising small companies in the research sector that has recently received public funding from the Eurostars Programme to develop its innovative activities.
It has raised €4.8m in the first close of a Series A investment round by a syndicate led by BioGeneration Ventures and INKEF Capital that also included companies MorphoSys and Hanzepoort as investors. Lanthio Pharma is a spin-off of the University of Groningen and launched in 2011 with seed funding from BioGeneration Ventures. The Series A round will remain open for one additional investor.
'THE INVESTMENT ROUND WILL REMAIN OPEN FOR ONE ADDITIONAL INVESTOR.'
Bart Wuurman, CEO of Lanthio Pharma commented: 'We are very pleased to welcome a number of new investors that offer Lanthio Pharma the opportunity to further develop its portfolio of innovative [...] drugs for diseases with high medical need.'
One of the many recognized benefits of participating in a Eurostars project is the credibility the programme offers to small companies looking for private investors.